Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
228 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Spinal Cord Injury - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Spinal Cord Injury - Pipeline Review, H1 2016', provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury - The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Spinal Cord Injury therapeutics and enlists all their major and minor projects - The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Spinal Cord Injury Overview 7 Therapeutics Development 8 Spinal Cord Injury - Therapeutics under Development by Companies 10 Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 13 Spinal Cord Injury - Pipeline Products Glance 14 Spinal Cord Injury - Products under Development by Companies 16 Spinal Cord Injury - Products under Investigation by Universities/Institutes 19 Spinal Cord Injury - Companies Involved in Therapeutics Development 20 Spinal Cord Injury - Therapeutics Assessment 54 Drug Profiles 65 Spinal Cord Injury - Recent Pipeline Updates 165 Spinal Cord Injury - Dormant Projects 204 Spinal Cord Injury - Discontinued Products 209 Spinal Cord Injury - Product Development Milestones 210 Appendix 219
List of Tables
Number of Products under Development for Spinal Cord Injury, H1 2016 16 Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Development by Companies, H1 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H1 2016 27 Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2016 28 Spinal Cord Injury - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 29 Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H1 2016 30 Spinal Cord Injury - Pipeline by Athersys, Inc., H1 2016 31 Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H1 2016 32 Spinal Cord Injury - Pipeline by BioAxone BioSciences, Inc., H1 2016 33 Spinal Cord Injury - Pipeline by FirstString Research, Inc., H1 2016 34 Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 35 Spinal Cord Injury - Pipeline by Histocell S.L., H1 2016 36 Spinal Cord Injury - Pipeline by Kadimastem Ltd., H1 2016 37 Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2016 38 Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H1 2016 39 Spinal Cord Injury - Pipeline by Lpath, Inc., H1 2016 40 Spinal Cord Injury - Pipeline by MandalMed, Inc., H1 2016 41 Spinal Cord Injury - Pipeline by Mapreg S.A.S., H1 2016 42 Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2016 43 Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2016 44 Spinal Cord Injury - Pipeline by New World Laboratories, Inc., H1 2016 45 Spinal Cord Injury - Pipeline by Omeros Corporation, H1 2016 46 Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H1 2016 47 Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H1 2016 48 Spinal Cord Injury - Pipeline by Protagenic Therapeutics Inc., H1 2016 49 Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H1 2016 50 Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 51 Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc., H1 2016 52 Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H1 2016 53 Spinal Cord Injury - Pipeline by SanBio, Inc., H1 2016 54 Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H1 2016 55 Spinal Cord Injury - Pipeline by StemCells, Inc., H1 2016 56 Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 57 Spinal Cord Injury - Pipeline by TissueGene, Inc., H1 2016 58 Spinal Cord Injury - Pipeline by Tumorend, LLC, H1 2016 59 Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 60 Spinal Cord Injury - Pipeline by Vicore Pharma AB, H1 2016 61 Assessment by Monotherapy Products, H1 2016 62 Assessment by Combination Products, H1 2016 63 Number of Products by Stage and Target, H1 2016 65 Number of Products by Stage and Mechanism of Action, H1 2016 68 Number of Products by Stage and Route of Administration, H1 2016 70 Number of Products by Stage and Molecule Type, H1 2016 72 Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2016 173 Spinal Cord Injury - Dormant Projects, H1 2016 212 Spinal Cord Injury - Dormant Projects (Contd..1), H1 2016 213 Spinal Cord Injury - Dormant Projects (Contd..2), H1 2016 214 Spinal Cord Injury - Dormant Projects (Contd..3), H1 2016 215 Spinal Cord Injury - Dormant Projects (Contd..4), H1 2016 216 Spinal Cord Injury - Discontinued Products, H1 2016 217
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
